PACTR202107562417077尚未招募3 期
A Global, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy, Safety, and Immunogenicity of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) in Adults Aged 18 Years and Older
ivzon Mabpharm Inc0 个研究点目标入组 22,500 人开始时间: 2021年7月23日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 22,500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 19 Year(s) 至 44 Year(s)（—）
- 性别
- All
入选标准
- •Voluntarily participate in this study and sign the informed consent form
- •Adults aged 18 years and older, male or female
- •According to the assessment of the investigator, the participant has a stable medical condition (which is defined as no significant changes in therapy or hospitalization caused by disease aggravation within 3 months before enrollment and are able to and willing to follow the requirements of the protocol
- •Males of reproductive potential and females of child-bearing potential voluntarily agree to take effective and acceptable contraceptive methods from the signing of informed consent form to 12 months after full-course immunization; females of child-bearing potential have negative pregnancy test at screening and at the day of vaccination
排除标准
- •History of previous COVID19 infection
- •Positive result for RTPCR test in screening period, or specific antibody IgG or IgM meet the following conditions
- •If both IgG and IgM are negative the participant can be vaccinated without waiting for the RTPCR test results
- •History of severe acute respiratory syndrome SARS middle east respiratory syndrome MERS and other human coronavirus infections or diseases
- •History of severe allergy to any vaccine eg acute allergic reactions, urticaria, skin eczema, dyspnea, angioneurotic edema or abdominal pain etc or be allergic to any components of V01
- •Any confirmed or suspected immunosuppression or immunodeficiency condition known from medical history, including human immunodeficiency virus infection asplenia
- •Serious or uncontrolled cardiovascular diseases, nervous system disorders eg Guillain-Barre syndrome blood and lymphatic system disorders, immune system disorders, hepatorenal disorders, respiratory system disorders e g active tuberculosis, pulmonary fibrosis metabolic and skeletal systems disorders or malignant tumors except for skin basal cell carcinoma or in situ carcinoma of uterine cervix that has been cured more than 5 years
- •Hereditary hemorrhagic tendency or coagulation dysfunction, or a history of thrombosis or hemorrhagic disease, or requirement of continuous use of anticoagulants
- •Prior use of any medications to prevent COVID19 e g use of antipyretics without pyrexia and any other symptoms
- •History of vaccination against SARSCoV2 marketed or investigational
- •Received attenuated live vaccine within 28 days before the first vaccination or any other vaccines licensed or investigational within 14 days before the first vaccination
- •Injection of immunoglobulin and/or other blood products within 3 months before the administration of inves
研究者
相似试验
尚未招募
3 期
A Phase III Clinical Trial of Influenza Virus Vector Covid-19 Vaccine for Intranasal Spray (DelNS1-2019-nCoV-RBD-OPT1)PACTR202110872285345Beijing Wantai Biological Pharmacy Enterprise Co Ltd.5,400
进行中（未招募）
不适用
A Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of ABT-894 versus Placebo in Subjects with Diabetic Neuropathic Paidiabetic neuropathic painMedDRA version: 9.1Level: LLTClassification code 10054095Term: Neuropathic painEUCTR2007-001140-47-CZAbbott GmbH & Co. KG110
进行中（未招募）
1 期
A Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of ABT-894 versus Placebo in Subjects with Diabetic Neuropathic Paidiabetic neuropathic painMedDRA version: 9.1Level: LLTClassification code 10054095Term: Neuropathic painEUCTR2007-001140-47-FRAbbott GmbH & Co. KG110
进行中（未招募）
1 期
A Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of ABT-894, Duloxetine and Placebo in Subjects with Diabetic Neuropathic Paidiabetic neuropathic painMedDRA version: 9.1Level: LLTClassification code 10054095Term: Neuropathic painEUCTR2007-001139-71-FRAbbott GmbH & Co. KG275
进行中（未招募）
不适用
A Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of ABT-894 versus Placebo in Subjects with Diabetic Neuropathic PaiEUCTR2007-001140-47-GBAbbott GmbH & Co. KG110